Eagle Pharmaceuticals Stock Price, Forecast & Analysis (NASDAQ:EGRX)

Eagle Pharmaceuticals trades on the NASDAQ under the ticker symbol "EGRX."

Eagle Pharmaceuticals Inc (NASDAQ:EGRX) issued its earnings results on Tuesday, November, 12th. The specialty pharmaceutical company reported $0.26 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.43 by $0.17. The specialty pharmaceutical company earned $41.10 million during the quarter, compared to analysts' expectations of $45.44 million. Eagle Pharmaceuticals had a net margin of 12.72% and a return on equity of 16.07%. The firm's revenue was down 19.9% on a year-over-year basis. During the same period in the previous year, the firm earned $1.18 EPS. View Eagle Pharmaceuticals' Earnings History.

Eagle Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Eagle Pharmaceuticals.

3 brokerages have issued 12-month price objectives for Eagle Pharmaceuticals' stock. Their forecasts range from $50.00 to $66.00. On average, they anticipate Eagle Pharmaceuticals' stock price to reach $58.00 in the next twelve months. This suggests a possible upside of 1.4% from the stock's current price. View Analyst Price Targets for Eagle Pharmaceuticals.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eagle Pharmaceuticals in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Eagle Pharmaceuticals.

Media coverage about EGRX stock has trended very negative recently, InfoTrie reports. The research firm rates the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Eagle Pharmaceuticals earned a coverage optimism score of -3.0 on InfoTrie's scale. They also assigned news stories about the specialty pharmaceutical company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future. View News Stories for Eagle Pharmaceuticals.

Eagle Pharmaceuticals saw a decrease in short interest during the month of October. As of October 15th, there was short interest totalling 1,560,000 shares, a decrease of 9.8% from the September 15th total of 1,730,000 shares. Based on an average daily volume of 149,500 shares, the days-to-cover ratio is presently 10.4 days. Currently, 11.9% of the shares of the stock are sold short. View Eagle Pharmaceuticals' Current Options Chain.

Some companies that are related to Eagle Pharmaceuticals include FibroGen (FGEN), Evotec (EVTCY), HUTCHISON CHINA/S (HCM), Taro Pharmaceutical Industries (TARO), Global Blood Therapeutics (GBT), Genmab A/S (GMAB), Emergent Biosolutions (EBS), Intercept Pharmaceuticals (ICPT), PTC Therapeutics (PTCT), Biohaven Pharmaceutical (BHVN), Deciphera Pharmaceuticals (DCPH), Myokardia (MYOK), Amicus Therapeutics (FOLD), Uniqure (QURE) and Arena Pharmaceuticals (ARNA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Eagle Pharmaceuticals investors own include Exelixis (EXEL), Gilead Sciences (GILD), Teekay Tankers (TNK), Celgene (CELG), GW Pharmaceuticals PLC- (GWPH), Intercept Pharmaceuticals (ICPT), Synergy Pharmaceuticals (SGYP), bluebird bio (BLUE), Radius Health (RDUS) and AbbVie (ABBV).

Eagle Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Chartwell Investment Partners LLC (1.37%), Smith Graham & Co. Investment Advisors LP (1.13%), Scout Investments Inc. (0.67%), Foundry Partners LLC (0.56%), Russell Investments Group Ltd. (0.52%) and Carillon Tower Advisers Inc. (0.43%). Company insiders that own Eagle Pharmaceuticals stock include Douglas L Braunstein, Hudson Executive Capital Lp, Sander A Flaum and Scott Tarriff. View Institutional Ownership Trends for Eagle Pharmaceuticals.

EGRX stock was sold by a variety of institutional investors in the last quarter, including Chartwell Investment Partners LLC, Scout Investments Inc., Systematic Financial Management LP, Convergence Investment Partners LLC, Alps Advisors Inc., Rhumbline Advisers, Strs Ohio and Hancock Whitney Corp. Company insiders that have sold Eagle Pharmaceuticals company stock in the last year include Douglas L Braunstein, Hudson Executive Capital Lp and Scott Tarriff. View Insider Buying and Selling for Eagle Pharmaceuticals.

EGRX stock was bought by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Chicago Equity Partners LLC, SG Americas Securities LLC, Alberta Investment Management Corp, California Public Employees Retirement System, Robeco Institutional Asset Management B.V., Wedge Capital Management L L P NC and State of Alaska Department of Revenue. View Insider Buying and Selling for Eagle Pharmaceuticals.

Shares of EGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of EGRX stock can currently be purchased for approximately $57.20.

Eagle Pharmaceuticals has a market capitalization of $781.92 million and generates $213.31 million in revenue each year. The specialty pharmaceutical company earns $31.90 million in net income (profit) each year or $2.09 on an earnings per share basis. Eagle Pharmaceuticals employs 96 workers across the globe.View Additional Information About Eagle Pharmaceuticals.

The official website for Eagle Pharmaceuticals is http://www.eagleus.com/.

Eagle Pharmaceuticals' mailing address is 50 TICE BOULEVARD SUITE 315, WOODCLIFF LAKE NJ, 07677. The specialty pharmaceutical company can be reached via phone at 201-326-5300 or via email at [email protected]